Its lead program, Zotatifin (eFT226/KHR187), is a differentiated eIF4A inhibitor that has demonstrated particularly compelling activity in combination therapy for ER+/HER2− metastatic breast cancer. In heavily pre-treated, CDK4/6-resistant patients, objective response rates and median progression-free survival exceed historical post-MONARCH benchmarks. These data supported FDA Fast Track designation and position the program as Phase 3–ready, with a credible path toward accelerated approval. Leading cancer centers are conducting investigator-initiated, federally funded trials, providing both scientific validation and meaningful non-dilutive capital.